SVRA vs. ORIC, HROW, ABUS, PHAR, CDMO, AVTE, PHAT, ZYME, YMAB, and CALT
Should you be buying Savara stock or one of its competitors? The main competitors of Savara include ORIC Pharmaceuticals (ORIC), Harrow (HROW), Arbutus Biopharma (ABUS), Pharming Group (PHAR), Avid Bioservices (CDMO), Aerovate Therapeutics (AVTE), Phathom Pharmaceuticals (PHAT), Zymeworks (ZYME), Y-mAbs Therapeutics (YMAB), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical preparations" industry.
Savara (NASDAQ:SVRA) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation.
ORIC Pharmaceuticals' return on equity of -38.08% beat Savara's return on equity.
Savara has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.
87.9% of Savara shares are owned by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are owned by institutional investors. 5.1% of Savara shares are owned by company insiders. Comparatively, 5.6% of ORIC Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Savara is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Savara had 1 more articles in the media than ORIC Pharmaceuticals. MarketBeat recorded 6 mentions for Savara and 5 mentions for ORIC Pharmaceuticals. ORIC Pharmaceuticals' average media sentiment score of 1.25 beat Savara's score of 0.58 indicating that ORIC Pharmaceuticals is being referred to more favorably in the news media.
Savara received 241 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. However, 66.20% of users gave ORIC Pharmaceuticals an outperform vote while only 66.06% of users gave Savara an outperform vote.
Savara currently has a consensus price target of $9.17, indicating a potential upside of 126.34%. ORIC Pharmaceuticals has a consensus price target of $20.00, indicating a potential upside of 129.62%. Given ORIC Pharmaceuticals' higher probable upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than Savara.
Summary
ORIC Pharmaceuticals beats Savara on 9 of the 13 factors compared between the two stocks.
Get Savara News Delivered to You Automatically
Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
